Skip to NavigationSkip to content

Donald Trump

Donald Trump causes confusion as to whether NHS will be 'on the table' in trade deal talks

President Donald Trump has caused confusion as to whether or not the NHS will ‘be on the table’ in post-Brexit trade deal negotiations with the United States.

Speaking at a press conference on Tuesday, Trump said: “Look I think everything with a trade deal is on the table. When you’re dealing with trade everything is on the table, so NHS, or anything else, or a lot more than that. Everything will be on the table, absolutely.”

Donald Trump says he will not accept campaign money from pharma

President Donald Trump has said he will not accept money from pharmaceutical companies in the run up to the 2020 elections.

Speaking at the Rx Heroin and Drug Abuse Summit in Atlanta, Trump said the industry “should be held accountable” for the role they played in the opioid crisis as he declared that he would not accept campaign contributions from pharma.

“My administration is also taking aggressive action to reduce the oversupply of highly addictive prescription drugs,” Trump said.

Trump ex-lawyer Cohen reveals Novartis pushed him to lobby

Image Credit: Chip Somodevilla/Getty Images

Among the swirling storm emanating from the testimony of Donald Trump’s ex-lawyer Michael Cohen to the House Oversight Committee, one of the many controversial claims to arise is that pharma firm Novartis allegedly attempted to coax him the President’s “fixer” into lobbying government on its behalf.

PhRMA blames hospitals for rising drug prices, hospitals association responds

Image Credit: Images Money

The American pharmaceutical industry trade lobby PhRMA has suggested that hospitals are to blame for high drug prices as the furore around drug pricing continues in the United States of America. The call comes after Donald Trump called on pharmaceutical companies to reduce the price of medicines.

Roche join Pfizer and others in price freeze while critics pose questions

Swiss multinational Roche has joined Pfizer and others in halting price hikes. However critics have condemned the move as observers pointed out that the roll backs may be less meaningful than first impressions might suggest.

Roche joined Pfizer, Novartis and MSD in announcing that it would freeze prices in the United States until the end of 2018. However critics have noted that the pharmaceutical company increased the price of nine key drugs by an average of 3% on 1 July of this year.

Trump forces Pfizer to back down and delay price hikes until 2019

Trump bared his teeth, and it paid off. Following his call-out of Pfizer after the US pharma giant ignored the President’s threats to crack down on drug prices and raised the price of 100 of its drugs, the firm has confirmed it will delay planned price hikes until the beginning of next year.

Trump slams Pfizer over price hikes, Pfizer responds

Price hiking in the pharmaceutical industry continues to persist, and has become ever more prominent in the public sphere thanks to in part to Donald Trump’s sporadic highlighting of the issue leading up to and throughout his presidency.

Top Ten most popular articles on Pharmafile.com this week

As the first week of July comes to an end we take a look over the most popular stories of the previous seven days.

While a series of scandals have drawn some of the big names into a web of legal issues, this week has offered a glimpse of hope as progress is made in innovative new treatments.

Proposed cuts to National Institutes of Health could delay up to 90% of US drug approvals

President Donald Trump’s budget proposes to cut funding to the National Institutes of Health by $7.2 billion or 21%. Researchers at the Washington University School of Medicine assert that this is a move which, given that the NIH funded more than 90% of new drugs, could prove to have dramatic consequences.

Ex-Lilly exec Trump’s nominee for health secretary

Alex Azar is officially President Trump’s nominee for the position as head of the Health and Human Services (HHS) agency, in a decision that was already widely expected.

The position has so far been a poisoned chalice in the Trump administration, with Azar likely to replace former incumbent, Tom Price, who resigned after it was revealed he had spent $1 million on private travel using private jets and military aeroplanes.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches